

Manuscript titled: **Infarct Core Growth During Inter-hospital Transfer For Thrombectomy Is Faster At Night, by P Seners et al.**

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2 (line 1)
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2 (line 1)
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4 (lines 50-57)
Objectives	3	State specific objectives, including any prespecified hypotheses	4 (line 58)
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	4 (lines 67-69), and supplemental methods
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4-5 (lines 67-91), and supplemental methods
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	4 (lines 68-77), supplemental methods
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4-5 (lines 79-91), and supplemental methods
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4-5 (lines 79-91), and supplemental methods

Bias	9	Describe any efforts to address potential sources of bias	4-5 (lines 75-77 and 97-99), and supplemental methods
Study size	10	Explain how the study size was arrived at	5 (line 102) and Figure 1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	supplemental statistical methods
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	5 (lines 93-99) and supplemental methods
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	NA
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	NA
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	
		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	5 (lines 97-99)
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Figure 1
		(b) Give reasons for non-participation at each stage	Figure 1
		(c) Consider use of a flow diagram	Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	5 (lines 102-106) and Table
		(b) Indicate number of participants with missing data for each variable of interest	NA
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	5 (lines 108-109)
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	5 (lines 108-111)

		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	5-6 (lines 109-118)
		(b) Report category boundaries when continuous variables were categorized	NA
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	6 (line 118) and supplemental results
Key results	18	Summarise key results with reference to study objectives	6 (lines 121-126)
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	7 (lines 146-151)
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	6 (lines 121-145)
Generalisability	21	Discuss the generalisability (external validity) of the study results	7 (lines 146-147)
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	8 (lines 159-162)

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).